Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vasopressin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A known ✓ | P37288 | 7/20 | 1.00 |
| ▸ | AVPR1B known ✓ | P47901 | 5/20 | 1.00 |
| ▸ | AVPR2 known ✓ | P30518 | 4/20 | 1.00 |
| ▸ | OXTR | P30559 | 4/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.88 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.72 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vasopressin SCHEMBL29688276 | 1.00 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL19712236 | 1.00 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL17874853 | 1.00 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL29530914 | 0.98 | AVPR1A (0.97) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL23879427 | 0.98 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL18476287 | 0.98 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL24390785 | 0.98 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL19733909 | 0.98 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL1172390 | 0.97 | AVPR1A (0.95) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL29500557 | 0.97 | AVPR1A (0.95) | AVPR1AAVPR1BAVPR2OXTRPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11207372-B2 | Vasopressin formulations for use in treatment of hypotension | PAR PHARMACEUTICAL, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200188474-A1 | PEPTIDE CONGENERS WITH POLYMER EXCIPIENTS | ASTORA WOMEN’S HEALTH LLC | 2020-06-18 | — | — | US | disclosed |
| US-20190201476-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | DAVA INTERNATIONAL, LLC | 2019-07-04 | — | — | US | disclosed |
| US-20190192615-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2019-06-27 | — | — | US | disclosed |
| US-20180185438-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | PAR PHARMACEUTICAL, INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180153955-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | PAR PHARMACEUTICAL, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9981006-B2 | Vasopressin formulations for use in treatment of hypotension | PAR PHARMACEUTICAL, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9925234-B2 | Vasopressin formulations for use in treatment of hypotension | PAR PHARMACEUTICAL, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925233-B2 | Vasopressin formulations for use in treatment of hypotension | PAR PHARMACEUTICAL, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170360877-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2017-12-21 | — | — | US | disclosed |
| US-20170290881-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2017-10-12 | — | — | US | disclosed |
| US-9750785-B2 | Vasopressin formulations for use in treatment of hypotension | PAR PHARMACEUTICAL, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170157203-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157203-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | AVPR2, AVPR1B, AVPR1A | AVPR1A 3/4885AVPR1B 2/4885AVPR2 1/4885 |
| US-20180185438-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | AVPR2, AVPR1B, AVPR1A | AVPR1A 3/4885AVPR1B 2/4885AVPR2 1/4885 |
| US-20180153955-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | AVPR2, AVPR1B, AVPR1A | AVPR1A 3/4885AVPR1B 2/4885AVPR2 1/4885 |
| US-20190201476-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | AVPR2, AVPR1B, AVPR1A | AVPR1A 3/4885AVPR1B 2/4885AVPR2 1/4885 |
| US-20170290881-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | AVPR2, AVPR1B, AVPR1A | AVPR1A 3/4885AVPR1B 2/4885AVPR2 1/4885 |
| US-20190192615-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | AVPR2, AVPR1B, AVPR1A | AVPR1A 3/4885AVPR1B 2/4885AVPR2 1/4885 |
| US-20200188474-A1 | PEPTIDE CONGENERS WITH POLYMER EXCIPIENTS | IAPP, VIP, NGLY1 | AVPR1A 217/4885AVPR1B 93/4885AVPR2 121/4885 |
| US-20170360877-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | AVPR2, AVPR1B, AVPR1A | AVPR1A 3/4885AVPR1B 2/4885AVPR2 1/4885 |
| US-11207372-B2 | Vasopressin formulations for use in treatment of hypotension | AVPR2, AVPR1B, AVPR1A | AVPR1A 3/4885AVPR1B 2/4885AVPR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.